abstract |
The present invention relates to PrP-derived peptide fragments with SEQ ID NO: 1 or SEQ ID NO: 2 or SEQ ID NO: 3 or SEQ ID NO: 4 for use as a medicament in the treatment of Αβ amyloidogenesis-related pathologies and/or Αβ-related toxicity, in particular of Alzheimer disease (AD), to a conjugate comprising PrP-derived peptide fragments with SEQ ID NO: 1 or SEQ ID NO: 3 and/or SEQ ID NO: 2 or SEQ ID NO: 4 and a carrier molecule, wherein the carrier molecule is a pharmacologically admissible molecule, preferably a low-generation dendrimer such as PAMAM dendrimer, and a method of manufacturing the above conjugate. |